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ABSTRACT  
Objective: In the present research work, oral gastro retentive dosage forms (GRDFs) of capecitabine (CPC) were formulated using floating 
concept.  
Methods: GRDFs were formulated using hydroxypropyl methyl cellulose (HPMC K4M and K15M) as drug release retardant, sodium 
bicarbonate (NaHCO3) and calcium carbonate (CaCO3) as gas generating agents, and micro crystalline cellulose (MCC), dicalcium phosphate 
(DCP), spray dried lactose (SDL), and pre gelatinized starch (PGS) as fillers. The tablets were prepared by direct compression method and 
evaluated for various parameters. The GRDFs were also characterized by Fourier-transform infrared spectroscopy (FTIR), and differential 
scanning calorimetry (DSC). 
Results and Discussion: All the formulations were subjected for pre and post compression parameters, shows all the data within the limits. 
The lag times of GRDFs has decreased significantly for formulations containing calcium carbonate when compared to sodium bicarbonate as gas 
generating agent. In vitro drug release studies indicate that higher polymer concentration delayed the CPC release, and the sustaining effect was 
in the order K4M > K15M > LVCR 100. Addition of MCC, DCP, SDL, and PGS as fillers further affected the lag time and in turn the CPC release 
rates.  
Conclusion: The formulation (F9) containing 10%w/w HPMC K4M as the release retardant, microcrystalline cellulose as filler and 20%w/w 
CaCO3 as gas generating agent fulfilled regulatory requirements in terms of percent drug release at the end of 24h. 
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INTRODUCTION 
Stomach cancer or gastric cancer refers to cancer arising 
from any part of the stomach. Gastric cancer is fourth most 
common worldwide cancer, with an estimated of 934,000 
new cases per year and the second most common cause of 
worldwide cancer deaths with an estimated 700,000 deaths 
annually1. Geographically, the incidence and prevalence rates 
are higher in Asia, Eastern Europe and South America than in 
Western Europe and North America2. 
5-Fluorouracil (5-FU) is one of the most widely used 
anticancer agents in the chemotherapy of solid tumors 
including gastric cancer. Treatment with 5-FU infusion 
requires either frequent hospitalizations or the use of central 
venous access device, harboring potential complications. 
Prodrugs of 5-FU like Tegafur and Doxifluridine have been 
developed to improve selectivity toward tumors than 5-FU. 
However, the oral administration of these drugs requires 
higher doses than intravenous injection due to first pass 
effects and moreover, adverse effects such as diarrhoea have 
been reported following the administration of Tegafur or 
Doxifluridine3, 4. These factors, together with the known 
patient preference for oral chemotherapy generated the need 
for an oral anticancer agent such as capecitabine (CPC) a 
tumor activating oral prodrug of 5-FU which improves safety 
and efficacy without or with fewer side effects. 
CPC (N4-pentyloxycarbonyl-5′-deoxy-5-fluorocytidine) is an 
oral fluoropyrimidine carbamate prodrug and has wider and 
more potent spectrum of antitumor activity than other 
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fluoropyrimidines administered at their maximum tolerated 
doses when tested against the xenograft models of human 
breast, cervical and bladder as well as gastric cancers5,6.  The 
efficacy of CPC has been shown to be additive with Irinotecan 
and supradditive with either Paclitaxel or Docetaxel and 
further higher antitumor activity with Trastuzumab or 
Bevacizumab than CPC alone6-8. 
Human pharmacokinetic studies have also shown that after 
oral administration, CPC is rapidly and almost completely 
absorbed through the gastrointestinal wall, thus avoiding 
direct intestinal exposure to 5-FU9. CPC is considered to be 
bio activated into 5-FU by three enzymes.After oral 
administration, CPC is first metabolized by carboxyl esterase 
in the liver to 5’-deoxy-5-fluoroctidune (5’-DFCR), which is 
then converted to 5’-deoxy-5-fluorouridine (5’-DFUR) by 
cytidine deaminase in the liver and tumor tissue. Finally, 5’-
DFUR is converted to 5-FU by thymidine phosphorylase, 
which is found at much higher levels in gastric cancer tissue 
than in normal tissue, enabling preferential activation of the 
active drug, 5’-FU, at tumor site10. CPC and its metabolites, 5’-
DFCR & 5’-DFUR, are not cytotoxic themselves, but become 
effective after conversion to 5’-FU. 
However, CPC also undergoes non enzymatic hydrolysis in 
aqueous buffers and may coverts to 5’- DFCR (Fig. 1)11. CPC 
is well absorbed from the gastrointestinal tract (GIT); its 
plasma half-life is about 45-60min and these properties 
make CPC as an ideal candidate for developing a GRDF for 
treating stomach/gastric cancers.Considering the above 
context of principles, the present investigation was aimed at 
developing a once-daily oral proto-type gastro retentive 
dosage forms of CPC based on the floating technology.  
 
O
OH
CH3 OH
N
N
F
NH
O
O
O
CH3
O
CH3 OH
OH
N
N
F
O
NH2
Hydrolysis in 0.1N HCl
Capecitabine 5'-DFCR
 
Figure 1: Acidic hydrolysis of CPC to 5’- DFCR 
 
MATERIALS AND METHODS 
Materials 
Capecitabine was obtained as a gift sample from Divi’s 
Laboratories, Hyderabad, India. HPMC K4M, HPMC K15M 
and HPMC LVCR 100, partially pre gelatinized starch were 
obtained from Colorcon Ltd, India. Sodium bicarbonate and 
calcium carbonate were purchased from CDH Pvt Ltd, India. 
Micro crystalline cellulose was obtained from FMC 
biopolymer, USA and spray dried lactose with maize starch 
was obtained from Roquette Pharma, France. Dicalcium 
phosphate, talc and magnesium stearate were purchased 
from Loba Chemie, India. All other reagents of analytical 
grade and all the solvents in HPLC are of HPLC grade.  
HPLC Method 
A reverse phase HPLC method was used for the analysis of 
CPC and 5’-DFCR in different samples. Chromatographic 
separation was performed on a Shimadzu Prominence HPLC 
system equipped with LC 10 AT VP binary pumps, SPD-10A 
VP UV Detector. LC solution software was used to collect and 
process the data. Mobile phase consisting of Acetonitrile: 
Ammonium acetate (50:50% v/v) was used and the mobile 
phase was filtered through nylon disc filter of 0.45µm 
(Millipore) and sonicated for 3min in ultrasonic bath before 
use. The flow rate was 1mL/min and the injection volume 
was 20µL. UV detection was performed at 268nm and the 
separation was achieved at ambient temperature. For 
quantitative analytical purpose, eluents were monitored at 
268nm and an Apollo C18 column (150mm x4.6mm, 5.0µ) 
was used and separation was carried out at ambient 
temperature with an injection volume of 20µL. The retention 
times for CPC and 5’-DFCR were 1.7min and 2.5min 
respectively. 
Stability Studies of CPC in 0.1N HCl 
10mg of CPC was dissolved in 10mL of volumetric flask 
containing 5mL of HPLC grade water and volume was made 
up to with the same, to yield 1mg/mL stock solution. The 
stock solution was subsequently diluted with 0.1N HCl to get 
20µg/mL; resulting solution was stored in an incubator at 
37°C. The samples were collected at different time intervals 
2, 4, 6, 8, 12, 24 & 48hrs. The samples were filtered and 
analyzed using the above developed HPLC method.   
Drug- Excipient Compatibility Studies: 
Fourier Transmittance Infrared Spectroscopy (FTIR) 
Studies: 
The FT-IR spectra of CPC and optimized formulation i.e. F9 
(containing CPC, HPMC K4M, CaCO3, MCC, Magnesium 
stearate and Talc) were measured using ATR-FTIR 
spectrophotometer (Bruker, Germany). ATR spectra were 
measured over the wave number range of 4000-500cm-1 at a 
resolution of 1.0cm-1. The powder sample is simply placed 
onto the ATR crystal and the sample spectrum is collected.  
Differential Scanning Calorimetry (DSC)Studies: 
Thermal analysis of CPC alone and CPC with selected 
excipients like NaHCO3, PGS, and optimized formulation i.e. 
F9 (containing CPC, HPMC K4M, CaCO3, MCC, Magnesium 
stearate and Talc) was performed using DSC instrument 
(DSC 200 F3 Maia, USA). The sample was sealed in a crimped 
aluminium pan by application of the minimum possible 
pressure and heated at a rate of 10ºC /min from 30-200ºC 
under nitrogen atmosphere. 
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Preparation of CPC Floating Tablets: 
CPC floating tablets were prepared by direct compression 
method (as per formulae given in Table I). All the 
ingredients were passed through sieve # 80 before mixing. 
Initially drug and polymers were mixed thoroughly and then 
required quantities of fillers were added and finally the 
blend was mixed with talc and mixed thoroughly for 5min in 
a poly bag and then required amount of magnesium stearate 
was added and mixed for another 5min. Powder blends (for 
50 tablets each) of all the above formulations were 
compressed on single punch tablet press (Cadmach, India) 
using 10mm punches (round shape) to a hardness of 4-6 
kg/cm2.
Table I: Composition of CPC floating tablets 
Ingredients 
(mg/tab) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
CPC 150 150 150 150 150 150 150 150 150 150 150 150 
HPMC K4M 40 60 80 100 - - 80 60 40 40 40 40 
HPMC K15M - - - - 80 - - - - - - - 
LVCR100 - - - - - 80 - - - - - - 
MCC 126 106 86 66 86 86 86 106 126 - - - 
PGS - - - - - - - - - 126 - - 
SDL - - - - - - - - - - 126 - 
DCP - - - - - - - - - - - 126 
NaHCO3 80 80 80 80 80 80 - - - - - - 
CaCO3 - - - - - - 80 80 80 80 80 80 
Magnesium Stearate 2 2 2 2 2 2 2 2 2 2 2 2 
Talc 2 2 2 2 2 2 2 2 2 2 2 2 
Total weight 400 400 400 400 400 400 400 400 400 400 400 400 
 
 
Evaluation Parameters for Powder Blends and 
Compressed CPC Tablets: 
Pre compression parameters of the prepared powder blend 
of all the formulations were determined by determining the 
bulk density, tapped density, compressibility index, 
hausner’s ratio and angle of repose12,13.  Compressed floating 
tablets were characterized for weight variation (n = 20), 
hardness (n = 6) was measured with a Monsanto tester 
Campbell Electronics (India), friability (n = 20), with a Roche 
type friabilator. The drug content in each formulation was 
determined by triturating 5 tablets in a mortar and powder 
equivalent to the 20mg was added in 20mL of HPLC grade 
water, followed by sonication for 15min. The solution was 
then filtered, suitably diluted with acetonitrile: ammonium 
acetate (75:25% v/v) and analyzed by HPLC method. 
In Vitro Drug Release Studies: 
The tablets were subjected to in vitro drug release studies 
using USP-Type II (paddle) dissolution rate test apparatus 
(LABINDIA, DS 8000) at a temperature of 37 ± 0.5ºC and 
50rpm. 900mL of 0.1N HCl was used as the dissolution 
medium. 5mL aliquots of the samples were withdrawn at 
specific time intervals over a period of 24hrs and filtered 
using a 0.45µm nylon disc filters and replaced with 5mL of 
fresh dissolution medium. The filtered samples were 
suitably diluted if necessary and analyzed for CPC & 5’-DFCR 
by the HPLC method as described above.  The dissolution 
experiments were conducted in triplicate. 
 
Drug release kinetics: 
The rate and mechanism of cumulative amount of CPC & 5’-
DFCR released from the prepared floating tablets were 
analyzed by fitting the dissolution data into the Zero-order, 
First-order, Higuchi and Korsmeyer-Peppas equations15-17. 
RESULTS AND DISCUSSION 
Stability Studies: 
The hydrolysis of CPC to 5’-DFCR was carried out by storing 
stock solution of CPC in 0.1N HCl at 37°C over a period of 
time. Samples were removed at different time points and 
subjected to HPLC analysis. From the stability data it is 
clearly evident that CPC was rapidly hydrolyzed to 5’-DFCR 
under non enzymatic acidic conditions with a half-life of 
0.73hrs (Fig.2)11. 
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Fig ure 2: Stability curves of CPC in 0.1 N HCl at 37°C. 
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Drug - Excipient Compatibility Studies: 
FTIR Studies: 
FTIR studies were carried with a view to evaluate the in situ 
CPC and excipients compatibility. FTIR spectra of CPC and F9 
were shown in Fig.3(A) and 3(B) respectively. Pure CPC 
showed characteristic IR absorption bands at 1038 cm-
1,1115 cm-1,1337 cm-1, 1645 cm-1, 1707 cm-1, 3516 cm-1, 
3178 cm-1  indicating the presence of C-N group, C-O-C group 
in aromatic ring, C-F group, C=N group, C=O group, bending 
of N-H group, and -OH groups respectively in CPC structure.  
These significant bands of CPC were also present in the FTIR 
spectra of CPC-excipient physical mixtures. These results 
indicate that compatibility of CPC with the selected 
excipients in formulation development studies. 
 
 
Figure 3 : FTIR spectra of CPC (A) and F9 (B) 
 
DSC Studies: 
DSC studies were also carried out to further investigate the 
chemical compatibility of CPC with the selected excipients. 
DSC thermograms of the CPC alone and CPC with the selected 
excipients and optimized formulation (F9) were shown in 
Fig.4.The CPC showed a sharp endothermic peak at around 
121ºC corresponding to its melting point17.The sharp 
endothermic at 121ºC corresponds to the melting point of 
CPC and was retained in all the thermograms of 1:1 w/w 
physical mixtures of the CPC and selected excipients like 
NaHCO3, PGS and also in optimized formulation (F9). These 
results indicated that the CPC was compatible with all the 
selected excipients in the formulations and there was no 
chemical interaction. 
 
 
Figure 4: DSC thermo gram overlay of CPC (A), CPC-PGS (B), CPC-NaHCO3 (C) and F9 (D) 
 
Pre and Post Compression Parameters: 
The results of various pre compression parameters (Carr’s 
index, Hausner’s ratio, and angle of repose) for powder 
blends of all formulations were found to be within the 
acceptable range and are suitable for  compression to tablets 
using direct compression method. The compressed tablets 
fulfilled the official compendial requirements with regarding 
drug content, uniformity of weight, hardness and friability, 
except with F11 and F12 where reproducibility of hardness 
was not achieved. 
In Vitro Drug Release Studies: 
In the present investigation, totally 12 different formulations 
were formulated using swellable hydrophilic polymers like 
HPMC of different grades (HPMC K4M and HPMC K15M) as 
release retardant materials and NaHCO3 and CaCO3 as gas 
generating agents and fillers like PGS, maize starch with SDL 
and DCP. Cumulative percent of CPC released i.e.  CPC & 5’-
DFCR together with different formulations at various time 
intervals were calculated. The floating lag times for all the 
formulations were determined and that for formulations F1-
A B 
C 
D 
B 
A 
Shaik et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2020; 10(3-s):199-205 
ISSN: 2250-1177                                                                                  [203]                                                                                 CODEN (USA): JDDTAO 
F5 containing NaHCO3 as gas generating agent were in the 
range of 10-38 sec, while that were with CaCO3 was in the 
range of 300-3600 sec. 
Effect of Release Retardant Concentration, Viscosity and 
Gas Generating Agent on CPC Release: 
Initial formulation studies were carried out to look in to the 
release retarding effect of HPMC K4M at concentration levels 
of 10, 15, 20, 25%w/w in F1-F4 respectively using 20%w/w 
NaHCO3 as gas generating agent and MCC as filler. F1, F2, F3, 
F4 gave an initial burst release of 23.74 ± 0.397%, 23.30 ± 
0.59, 20.15 ± 0.08% and  17.73 ± 0.73% respectively at the 
end of 1hr and a complete CPC release was attained at the 
end of 16hrs and 20hrs for F1 and F2 respectively, whereas 
94.4 ± 2.19% and 91.28 ± 0.09% for F3 and F4 respectively 
at the end of 24hrs. In all the cases the tablets were intact 
and a gel layer was retained up to 24hrs.  The comparative 
dissolution profiles of F1-F4 were shown in Fig.5 (A). From 
the results it can be concluded that the HPMC K4M at 
concentration levels of 20%w/w and 25%w/w was able to 
retard the release of CPC, a water soluble drug, from floating 
tablets over a period of 24hrs successfully and moreover, 
there is no statistical significant difference between the 
cumulative amount of CPC released, the HPMC 20% w/w 
concentration was selected further to investigate the effect 
of HPMC viscosity on release of CPC from floating tablets. 
Further studies were carried out by developing F5 with 
20%w/w HPMC K15M as release retardant, gave a 15.54 ± 
0.7% of initial burst release at 1hr and 97.39 ± 0.37% at end 
of 24hrs, tablet was intact and a gel layer remained at end of 
24hrs. The comparative dissolution profile of F3 and F5 
were shown in Fig. 5(B).From the results it can be concluded 
that the viscosity of HPMC has a little effect in the lag time 
values. However, the % CPC released from floating tablets 
was not affected and may be due to the water soluble nature 
of CPC.  An attempt was also made with 20%w/w LVCR 100 
(F6) (data was not considered) a low viscosity grade 
polymer however; the tablets were dissolved within 30min.
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Fig.5: Comparative drug release profiles of - (A) HPMC K4M formulations at different concentrations with NaHCO3; (B) 
formulations with different viscosities of HPMC with NaHCO3 
Even though a continuous and sustained release of CPC was 
observed with F3 over a period of 24hrs, reproducibility of 
hardness is a problem when NaHCO3 was used as a gas 
generating agent. Hence, further trials were carried out by 
replacing NaHCO3 with CaCO3 at same percent levels in the 
formulations i.e. 20%w/w. F7- F9 were compressed with 
CaCO3 as gas generating agent containing 20%w/w, 
15%w/w and 10%w/w of HPMC K4M levels in floating 
tablets. F7, F8, F9 gave an initial burst release of 10.56 ± 
0.44%, 19.39 ± 0.57% and 23.0 ± 3.73% respectively at end 
of 1hr and 80.06 ± 0.53%, 82.68 ± 0.34% and 97.12 ± 1.26% 
respectively at 24hrs time interval. 
Overall, the CPC release was found to be inversely related to 
the concentration of HPMC present in the matrix structure 
i.e. higher the concentration the slower is CPC release from 
tablets. This was further confirmed by the MDT values. 
Moreover the increase in HPMC concentration also affected 
the floating lag time values i.e. lower the HPMC 
concentration lower the lag time values. Comparative 
dissolution profiles for F3 (containing NaHCO3) and F7 were 
given in Fig. 6(A).The comparative dissolution profile of F7, 
F8 and F9 were shown Fig.6 (B).  
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Figure 6: (A) -Comparative drug release profiles of formulations with NaHCO3 (F3) and CaCO3 (F7); (B) - Comparative 
drug release profiles of formulations with HPMC K4M at different concentrations with CaCO3 
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Effect of Fillers on Lag Time Value: 
Effect Fillers such as PGS (F10), SDL with maize starch (F11) 
and DCP (F13) on CPC release was investigated. F10 gave a 
CPC release of 22.70 ± 1.02 % at 1hr and 99.54 ± 0.55% at 
the end of 24hrs. F10 though sustained the release of CPC 
from the floating tablets up to 24hrs; the lag time was 
significantly more when compared to F9 containing MCC as 
filler. The comparative dissolution profile for F9 and F10 is 
shown in Fig. 7. For F11 and F12 the reproducibility of 
hardness was a problem and tablets were not fulfilled the 
pharmacopoeial specifications. 
Overall, the F9 containing 10%w/w HPMC K4M as the 
release retardant, MCC  as filler and  CaCO3 20%w/w as gas 
generating agent floated within 5 ± 0.3min and gave a good 
burst release of CPC (23.80 ± 3.73%) followed by controlled 
release of CPC (97.121 ± 1.26%) over a period of 24 hrs. The 
calculated MDT (min) value for formula F9 is 267min. F9 also 
fulfilled the regulatory requirements in terms of percent 
drug release (not less than 85% at the end of dissolution 
studies i.e. 24hrs)18. 
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Figure 7: Comparative drug release profiles of formulations with MCC (F9) and PGS (F10) 
 
Drug Release Kinetics and mechanism: 
The results of kinetic models for CPC & 5’-DFCR release from 
floating tablets were shown in Table II. The coefficient of 
correlation (R2) was used as an indicator of the best fitting 
for each of the models considered. The results reveal that all 
formulations best fit in the First order model. The 
mechanism of drug release from these tablets was found to 
be diffusion, as seen from high R2values of the Higuchi model. 
The data obtained were fitted in the Korsmeyer-Peppas 
model in order to find out the n value. The release showed a 
high correlation with the Korsmeyer-Peppas model. The n 
value ranged from 0.45 to 0.66, which suggested that drug 
release from the mixture of polymers was non-Fickian 
diffusion controlled and was influenced by both swelling and 
erosion of floating tablets. 
 
Table II: In vitro release kinetic parameters of CPC floating tablets 
 
 
 
Formulation 
Zero order First order Higuchi Peppas MDT 
(min) R2 K0(h-1) R2 K1(h-1) R2 Kn(h-1/2) R2 N 
F1 0.82 3.83 0.96 0.16 0.99 24.41 0.99 0.50 377 
F2 0.92 4.52 0.86 0.16 0.99 22.22 0.99 0.45 511 
F3 0.91 3.74 0.98 0.11 0.95 20.21 0.96 0.49 534 
F4 0.92 3.73 0.98 0.10 0.99 20.74 0.99 0.53 571 
F5 0.89 3.80 0.98 0.13 0.98 20.85 0.99 0.56 517 
F6 - - - - - - - - - 
F7 0.96 3.14 0.98 0.06 0.98 16.59 0.99 0.66 810 
F8 0.87 3.19 0.98 0.07 0.98 17.70 0.99 0.48 581 
F9 0.80 3.73 0.99 0.15 0.96 19.48 0.99 0.59 267 
F10 0.82 3.81 0.94 0.19 0.97 21.51 0.99 0.60 250 
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CONCLUSION 
From the results obtained it can be concluded that, 
developing a once-daily oral proto-type gastro retentive 
dosage forms GRDFs of CPC based on the floating technology 
may increase the CPC pharmacotherapy as the CPC is 
released locally in the stomach leading to high drug 
concentrations at the gastric mucosa over a period of time in 
continuous manner thus reducing the frequency of 
administration. Overall, the floating tablet formulations may 
result in effective treatment of stomach cancer when 
compared to the existing immediate releasetablets.  
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